secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0000950170-24-003621
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA reports preliminary FY2023 revenue $49.8M (+46% YoY), signs PermeaDerm distribution deal
--------------------------------------------------------------------------------

- Q4 2023 commercial revenue ~$14.1M (+50% YoY); full-year 2023 commercial revenue ~$49.8M (+46% YoY).
- FY2023 gross margin ~84.5%; cash, equivalents and marketable securities ~$89.1M as of Dec 31, 2023.
- FY2024 revenue guidance $78.5M–$84.5M (+57%–69% YoY); Q1 2024 guidance $14.8M–$15.6M (+42%–50% YoY).
- Exclusive multi-year distribution agreement with Stedical Scientific for PermeaDerm in the US; 5-yr initial term, 50% gross margin on sales.
- Completed enrollment in TONE post-market vitiligo study (109 patients); 12-month follow-up with 6-month primary endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/0000950170-24-003621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024003621/rcel-20240110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-003621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer